key: cord-0959400-ydehdww9
authors: Bollavaram, Keval; Leeman, Tiffanie H.; Lee, Maggie W.; Kulkarni, Akhil; Upshaw, Sophia G.; Yang, Jiabei; Song, Hannah; Platt, Manu O.
title: Multiple Sites on SARS-CoV-2 Spike Protein are Susceptible to Proteolysis by Cathepsins B, K, L, S, and V
date: 2021-02-17
journal: bioRxiv
DOI: 10.1101/2021.02.17.431617
sha: 06b599a1da7745aa38c708f3037d14d0674eaa83
doc_id: 959400
cord_uid: ydehdww9

SARS-CoV-2 is the coronavirus responsible for the COVID-19 pandemic. Proteases are central to the infection process of SARS-CoV-2. Cleavage of the spike protein on the virus’s capsid causes the conformational change that leads to membrane fusion and viral entry into the target cell. Since inhibition of one protease, even the dominant protease like TMPRSS2, may not be sufficient to block SARS-CoV-2 entry into cells, other proteases that may play an activating role and hydrolyze the spike protein must be identified. We identified amino acid sequences in all regions of spike protein, including the S1/S2 region critical for activation and viral entry, that are susceptible to cleavage by furin and cathepsins B, K, L, S, and V using PACMANS, a computational platform that identifies and ranks preferred sites of proteolytic cleavage on substrates, and verified with molecular docking analysis and immunoblotting to determine if binding of these proteases can occur on the spike protein that were identified as possible cleavage sites. Together, this study highlights cathepsins B, K, L, S, and V for consideration in SARS-CoV-2 infection and presents methodologies by which other proteases can be screened to determine a role in viral entry. This highlights additional proteases to be considered in COVID-19 studies, particularly regarding exacerbated damage in inflammatory preconditions where these proteases are generally upregulated.

Proteases are central to the infection process of SARS-CoV-2 1 , the coronavirus responsible for the COVID-19 pandemic 2 . Cleavage of the spike protein on the virus's capsid into S1/S2 subunits causes the conformational change that leads to membrane fusion and viral entry into the target cell 3 . This can happen at the cell surface through the action of the membrane bound protease, TMPRSS2 4 and soluble, extracellular furin 5 , and also after endocytosis of the virion facilitating endolysosomal escape through proteolytic activity of cysteine cathepsins B and L 6 in acidic microenvironments 1 . These proteases have been the primary focus and implicated in SARS-CoV or SARS-CoV-2 infection 7 , but a number of other proteases may be contributing to spike protein activation, but have not yet been implicated 8 . Since inhibition of one protease may not be sufficient to block SARS-CoV-2 entry into cells 4 , other proteases that may play an activating role and hydrolyze the spike protein must be identified.

Cathepsins B and L have already been implicated in cleavage of SARS-CoV-2 spike protein 4 , and there have been strong suggestions to prioritize cathepsin L inhibitors for COVID-19 therapies that have already been developed -some are even FDA approved 9 . Cathepsins K, S, and V share 60% sequence homology with cathepsin L with cathepsin V actually sharing 80% sequence homology with cathepsin L 10 . These cathepsins are also promiscuous with their substrates, suggesting cross-reactivity 11 .

Here, we test the hypothesis that the spike protein might have sites susceptible to cleavage by cathepsins K, S, or V and suggest additional mechanisms by which proteases are involved in SARS-CoV-2 infection. SARS-CoV-2 infection and severity of COVID-19 were shown to be elevated in patients with pre-existing conditions, resulting in a greater risk of mortality in those patients 12 . These pre-existing conditions include diseases that are associated with upregulation of cathepsins K, L, S, and V such as diabetes [13] [14] [15] , hypertension [16] [17] [18] , sickle cell disease 19, 20 , cardiovascular disease 14, 21 , and emphysema 22, 23 . Together, this led us to investigate spike protein amino acid sequences preferred in the active site of these cathepsins for peptide bond hydrolysis.

Here, we used an unbiased approached, applying computational methods to determine the potential of other closely related cysteine cathepsins to bind to and cleave the spike protein. Computational analyses of the SARS-CoV-2 genome-encoded protease necessary for viral replication 24 suggested inhibitor molecules and strategies, but the focus here was to investigate human proteases that could also be targeted for inhibition. We used a program we previously developed called PACMANS, Protease-Ase Cleavages from MEROPS ANalyzed Specificities 25 to determine putative cleavage site locations on SARS-CoV-2 spike protein. This algorithm works with users' input of a substrate peptide's amino acid sequence for cleavage by an identified protease that is included in the MEROPS database 26 . PACMANS uses a sliding-window approach, where individual sub-sequences that fill the active site pocket are scored, based on amino acids preferred at the active site of the particular protease for maximal hydrolytic ability against a region on the input substrate to generate scores for preferred cleavage sites. This pocket slides along the length of the substrate amino acid sequence, scores all possible 8-amino acid sub-sequences, then ranks them by the normalized version of this score. PACMANS also calculates a normalized score to enable comparisons across multiple proteases on the same substrate. Coupling sequence analysis with molecular docking tools, together, are an unbiased approach presented here to rationally identify other protease targets for new therapeutics against SARS-CoV-2, its infectivity, disease severity, and potentially longer-term complications 27 .

Using PACMANS, possible putative cleavage sites on SARS-CoV-2 spike protein, the substrate, were identified with furin and cathepsins B, K, L, S, and V as the proteases. Furin, and cathepsins B and L have already been identified to cleave spike protein in previous studies 4, 5 . From PACMANS analysis, furin had the highest scoring cleavage site and identified its cleavage at the RRAR / SVAS site known to be the activating cleavage at S1/S2 site that causes conformational change and membrane fusion 5 (Table 1) . This confirms that PACMANS does identify valid cleavage sites along the full length of the spike protein based solely on the amino acid sequence and its susceptibility to hydrolysis by these proteases. Cathepsin B, like furin, also prefers basic amino acid residues at its active site, and scored high at multiple sites on spike protein.

Putative cleavage sites for cathepsins B, K, L, S, and V are included in the rank ordered list sorted by their normalized scores. Cleavage sites were identified in multiple domains of the spike protein (Table 1) .

High ranking cleavage sites in the S1/S2 region was also identified for cathepsin K at amino acid 700 at the S2' site which was the 7 highest rank according to PACMANS. A number of sequences were identified as highly ranked for their susceptibility to multiple proteases, indicating a strong likelihood of cleavage by one or more proteases. Ranks indicate the preferred site on spike protein for each specific protease, so each protease has a rank#1 for highest preference in the table for cleaving spike protein. The normalized score allows for comparison across all the proteases for the same substrate. There were potential cleavage sites in all regions of the spike protein including the receptor binding domain, the S1/S2 cleavage domain for spike protein activation, N-terminus, C-terminus, and heptad repeat domains by cathepsins B, K, S, V and L. Cathepsin B's highest score region was in the S1 domain. Cathepsins K and V had the same top ranked site in the heptad repeat region, cathepsin S was highest scored in the S2 region, and cathepsin L was in the receptor binding domain.

Since PACMANS only analyzes the sequence of amino acids, consideration for the three-dimensional structure was helpful to determine access of the protease active sites to dock within close proximity of the spike protein sequence for cleavage is necessary. To assess this separately in an unbiased manner, furin, and cathepsins B, 

The spike protein has two key domains, S1 subunit contains angiotensin I converting enzyme 2 (ACE2) receptor binding domain and S2 domain mediates membrane fusion 28 . S1/S2 site is the critical site where cleavage of spike protein by proteases causes a conformational change promoting virus entry to the host cells. The locations of putative maturation sites S1/S2 site 1 and site 2 as well as S2' on the SARS-CoV-2 spike protein sequence were detailed by Coutard et al. 5 . The regions surrounding these cleavage sites were highlighted areas of analysis. From PACMANS, the rankings are represented by a heatmap with green indicating higher probability of cleavage and red indicating lower. Furin ranked highest at the previously identified furin cleavage sites S1/S2 Site 1 and S2' (yellow stars), as expected ( Figure 2 ). Cathepsins K, L, S, and V also shared high PACMANS rankings just outside the canonical S1/S2 Site 2, at MSLG/AENS (blue star), suggesting these proteases may also be involved in cleavage that might induce conformational change and membrane fusion. Additional sites such as VTLA/DAGF (pink star) also demonstrated high probabilities of cleavage across multiple cathepsins, with rankings in the top 20 for cathepsins B, K, L, S, and V ( Figure 2 ).

All four cathepsins, cathepsins K, S, L and V showed high ranks for two of the identified sequences on spike protein, so these were investigated more closely. SVLH/STQD (46) (47) (48) (49) (50) (51) (52) (53) in N-terminus domain and MSLG/AENS (697-704) just outside the S2' site were the two sequences ( Figure 3 ). Three of the cathepsins showed high ranked scores for other sequences. SALE/PLVD (221-228) was scored to be susceptible to cleavage by cathepsins S, V and K in the N-terminus domain ( Figure 4A ). Cathepsins S, L, and V also showed high ranks for ELLH/APAT (516-523) in the receptor binding domain, and NGLT/VLPP (856-863) in the S2 domain ( Figure 4B ,C).

With multiple cathepsins having preferred cleavage sites on SARS-CoV-2 spike protein, we proposed the hypothesis that cleavage by cathepsins at multiple sites could be inactivating cleavage events. For example, if two proteases hydrolyzed spike protein at adjacent regions, freeing a part of the protein, then the peptide fragment released could be destabilizing to protein conformation. Using high ranked sequences and molecular docking, cleavage events that would produce fragments were examined. We For cleavage in the S1/S2 region, again the site susceptible to cleavage by multiple cathepsins were analyzed. G700 -G769 (7 kDa fragment), G700 -V860 (17 kDa fragment), and T768 -V860 (10 kDa fragment) were modeled ( Figure 6 ).

Fragments are shown assuming the proteases are cleaving from the protomer of the spike protein, and from the assembled trimer of spike protein. This S1/S2 region is where proteolytic cleavage can be activating, meaning it promotes the conformational change that causes viral membrane fusion with cell membrane and subsequent viral entry. However, if there were multiple cleavage events freeing a fragment from the total spike protein, then the fusion event may not occur when these multiple cathepsins are present.

To assess the results from our computational analyses, we conducted The fragment sizes generated reflect some of the predicted cleavage sizes suggested by PACMANS analysis. For example, cathepsin K was suggested to cleave spike protein at G700 and G769 which would generate three fragments: 7 kDa, 56 kDa, 78 kDa ( Figure 6 ); a 78 kDa band appears in the blot. Cathepsin S was suggested to cleave spike protein at both G700 and V860 to release a 17 kDa fragment, but also 46 kDa and 78 kDa fragments; while the 78kDa fragment is not detected, there is a band at 46 kDa and the lower 17 kDa. CatV also has this 46 kDa band as it was suggested to cleave at both of these sites as well. Fragments below 20 kDa in size are present for all of the proteases tested except for cathepsin B. A number of other calculations of band sizes from cleavage fragments can be done, but the validation of specific sequences will need to be done by mass spectrometry to specifically identify peptide fragments that, when re-assembled, recapitulate full length spike protein. However, these computational tools help motivate those further analyses with suggestive hypotheses of multiple cathepsin cleavage events.

From our computational-based PACMANS analysis and computational simulation of protein docking analysis, spike protein is susceptible to cleavage by cathepsins B, K, L, S, V, and furin at multiple sites, which can impact the infectivity and cell entry by SARS-CoV-2. This is the first implication of cathepsins K, S, and V for a role in COVID-19, but we have shown in this computational study that they can potentially cause a maturation cleavage event near the S2' site that facilitates membrane fusion. A table containing a rank ordered list of sites where cathepsins might cleave spike protein was generated, and we identified two locations that cathepsins K, L, S and V all showed high sequence cleavage preference. As summarized in Table 1 and figures 3 Cardiac injury has been an important factor associated with mortality of COVID-19 31 . ACE2, the cell receptor that binds spike protein, has previously been shown to be upregulated in cardiomyocytes in patients with cardiovascular disease 32 , and SARS-CoV-2 infection of induced pluripotent stem cell-derived cardiomyocytes has been confirmed 33 . In a separate study, RNA sequencing showed that ACE2 as well as cathepsins B and L where highly expressed in human induced pluripotent stem cellderived cardiomyocytes, but interestingly, the protease TMPRSS2 was only expressed at low levels 34 . This shows that COVID-19 infection in cardiomyocytes may proceed through cathepsin-mediated pathways more so than TMPRSS2-mediated mechanisms; therefore, confirmation studies need to be completed. It is well reported that protease inhibitors reduce viral infection. FDA approved protease inhibitors used to suppress COVID-19 infection found that ritonavir was most effective at inhibiting SARS-CoV-2 main protease and human TMPRSS2. Cathepsins B and L were also capable of being blocked by indinavir and atazanavir 35 . Again, the other proteases implicated by the results of this study have not been tested but may also be targeted by these inhibitors as well, as cathepsin inhibitors have been notoriously cross-reactive [36] [37] [38] [39] . Though we find this study to be useful, there are limitations to be considered.

The results presented identify hypothetical protease cleavage sites on SARS-CoV-2-S, and spike protein hydrolysis by cathepsins K, S, and V was verified with recombinant in vitro studies. However, confirmation of the identity of these sequences to confirm they match with PACMANS predictions must be completed with mass spectrometry or sitedirected mutagenesis for confirmation. The benefits of the computational approaches applied here are that a process has been presented of PACMANS followed by molecular docking to generate hypotheses for investigating other proteases, even beyond those included in this study. Upregulated plasmin, thrombin, and other serine proteases may be present at the site as well, implicated in the hypercoagulable state induced by SARS-CoV-2 infection 48 . Another example involves the D614G SARS-CoV-2 spike mutant that has been shown to be a more infectious virus with an enhanced susceptibility of spike protein to furin cleavage, while also altering the dynamics of the spike protein conformation 49 . This site was not identified in the unbiased approach used in the studies presented here, but if other mutations are identified, they can be input into PACMANS to determine their putative result on activating cleavage. Another study identified a cleavage site on spike protein from SARS-CoV, the virus that caused the SARS outbreak in 2009, at position T678 8 , but that site also was not highly ranked in the unbiased approaches used here. Despite these sites not appearing in the analysis, we are confident that the PACMANS analysis identifies cleavage sites as the furin site was the top ranked site, and additional cleavage sites that had been validated by other experimental approaches were identified from this analysis.

The extension from these analyses would be the further discovery of the role multiple cathepsins interacting, binding, and cleaving spike protein in activating or inactivating ways that can be taken in the aggregate to predict the responses in cells and tissues when exposed to SARS-CoV-2. We also have identified interactions of cathepsins with each other that remove them from the system, as they work in a proteolytic network and affect substrate degradation 50 . Together, these systems considerations of multiple cathepsins working with or against other proteases in the presence of spike protein during SARS-CoV-2 infection may yield insight into optimizing pharmaceutical targeting to mitigate the effects. in the S1 and S2 regions were ranked using PACMANS, and scores are shown with a heat map. Heat scores of ranks are colored from green to red, with green indicating a higher rank (closer to 1) and red indicating lower rank (greater numbers) that are less likely to be susceptible to cleavage by the specific protease. Boxed sequences indicate published cleavage sites of spike protein that promote conformational change for entry to cell. Stars indicate locations where multiple proteases have higher scores of cleavage probability: yellow for furin, blue for the cathepsins K, L, S, and V near S1/S2 site, and pink for cathepsins K, L, S, and V cleaving outside the S2' site. From the docking software, fragments created from cleavage by two or more cathepsins at two sites in the S1/S2 region of spike protein are shown for (A), G700 -G769, 7 kDa fragment (B), T768-V860, a 10 kDa fragment and (C) G700 -V860, a 17 kDa fragment.

Fragments are shown from the protomer and from the trimer for each cleavage site pair. Samples were collected and prepared for reducing immunoblot with anti-SARS-CoV-2 spike. Representative blot after 10 minutes of incubation is shown.

Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV

China Novel Coronavirus I, Research T (2020) A Novel Coronavirus from Patients with Pneumonia in China

Structure, Function, and Evolution of Coronavirus Spike Proteins

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade

SARS coronavirus, but not human coronavirus NL63, utilizes cathepsin L to infect ACE2-expressing cells

Proteolytic activation of the SARS-coronavirus spike protein: cutting enzymes at the cutting edge of antiviral research

Cathepsin L functionally cleaves the severe acute respiratory syndrome coronavirus class I fusion protein upstream of rather than adjacent to the fusion peptide

Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patients

Manipulating substrate and pH in zymography protocols selectively distinguishes cathepsins K, L, S, and V activity in cells and tissues

Cysteine cathepsins: from structure, function and regulation to new frontiers

China Medical Treatment Expert Group for C (2020) Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis

Increased cathepsin K and tartrateresistant acid phosphatase expression in bone of streptozotocin-induced diabetic rats

Increased serum cathepsin S in patients with atherosclerosis and diabetes

Cathepsin L is crucial for the development of early experimental diabetic nephropathy

Cathepsin K knockout alleviates pressure overload-induced cardiac hypertrophy

Superoxide-dependent cathepsin activation is associated with hypertensive myocardial remodeling and represents a target for angiotensin II type 1 receptor blocker treatment

Angiotensin II-Induced vascular remodeling and hypertension involves cathepsin L/V-MEK/ERK mediated mechanism

Sickle cell disease activates peripheral blood mononuclear cells to induce cathepsins k and v activity in endothelial cells

Sickle Cell Anemia Mediates Carotid Artery Expansive Remodeling That Can Be Prevented by Inhibition of JNK (c-Jun N-Terminal Kinase)

Cysteine protease cathepsins in cardiovascular disease: from basic research to clinical trials

Inducible targeting of IL-13 to the adult lung causes matrix metalloproteinase-and cathepsin-dependent emphysema

Cathepsin K: The Action in and Beyond Bone

Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL (pro)) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates

PACMANS: A bioinformatically informed algorithm to predict, design, and disrupt protease-on-protease hydrolysis

MEROPS: the database of proteolytic enzymes, their substrates and inhibitors

Anticipating the long-term cardiovascular effects of COVID-19

Inhibitors of SARS-CoV-2 Entry: Current and Future Opportunities

Emerging roles of cysteine cathepsins in disease and their potential as drug targets

Cathepsin L Helps to Defend Mice from Infection with Influenza A

Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan

Cell type-specific expression of the putative SARS-CoV-2 receptor ACE2 in human hearts

SARS-CoV-2 infection of human iPSC-derived cardiac cells predicts novel cytopathic features in hearts of COVID-19 patients

SARS-CoV-2 infects and induces cytotoxic effects in human cardiomyocytes

Potential protease inhibitors and their combinations to block SARS-CoV-2

Cathepsin S inhibitors

Cathepsin B and L inhibitors: a patent review (2010 -present)

Merck &Co. drops osteoporosis drug odanacatib

Endothelial cells and cathepsins: Biochemical and biomechanical regulation

Cytokine Circuits in Cardiovascular Disease

Vasa Vasorum Angiogenesis: Key Player in the Initiation and Progression of Atherosclerosis and Potential Target for the Treatment of Cardiovascular Disease

Cysteine Protease Cathepsins in Atherosclerotic Cardiovascular Diseases

Endothelial dysfunction in cardiovascular disease and Flammer syndromesimilarities and differences

COVID-19: In the Eye of the Cytokine Storm

Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells

Tumor necrosis factor alpha stimulates cathepsin K and V activity via juxtacrine monocyte-endothelial cell signaling and JNK activation

Cystatin C deficiency in human atherosclerosis and aortic aneurysms

Elevated Plasmin(ogen) as a Common Risk Factor for COVID-19 Susceptibility

Spike mutation D614G alters SARS-CoV-2 fitness

Reassessing enzyme kinetics: Considering protease-as-substrate interactions in proteolytic networks

The ClusPro web server for protein-protein docking

Computational predictions of cysteine cathepsin-mediated fibrinogen proteolysis

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

 Table 1